Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…

Background: Estimates on the epidemiology of chronic non-cancer pain vary widely
throughout Europe. It is unclear whether this variation reflects true population differences or …

Importance Developing effective vaccines against Ebola virus is a global priority. Objective
To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV…

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

Background Despite the availability of effective vaccines against COVID-19, booster
vaccinations are needed to maintain vaccine-induced protection against variant strains and …

BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an …

Background Information on the incidence of serious infections in children in general practice
is scarce. However, estimates on the incidence of disease are important for several reasons…